Reassessing AbCellera Biologics (ABCL) After A Sharp 16.8% Weekly Share Price Drop [Yahoo! Finance]
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
AbCellera Biologics (NASDAQ:ABCL) was downgraded by analysts at
Wall Str
AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 [Yahoo! Finance]
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause [Yahoo! Finance]